↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Träfflista för sökning "WFRF:(Kryachok I) "

Search: WFRF:(Kryachok I)

Result 1-4 of 4

Sort/group result

Sort by: Hits per page:

Enumeration	Reference	Cover	Find
1.	Bilous, N, et al. (author) Alterations in the natural killer cell repertoire in myelodysplastic syndromes 2007 In: HAEMATOLOGICA-THE HEMATOLOGY JOURNAL. - 0390-6078. ; 92, s. 405-405 Conference paper (other academic/artistic)
2.	Osterborg, A, et al. (author) Ofatumumab (OFA) Vs. Physician's Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242 2014 In: BLOOD. - 0006-4971. ; 124:21 Conference paper (other academic/artistic)
3.	Osterborg, A, et al. (author) Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia 2016 In: Leukemia & lymphoma. - : Informa UK Limited. - 1029-2403 .- 1042-8194. ; 57:9, s. 2037-2046 Journal article (peer-reviewed)
4.	Miklos, U., et al. (author) Five-year survival follow-up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine-refractory chronic lymphocytic leukaemia: a short report 2020 In: British Journal of Haematology. - : Wiley. - 0007-1048 .- 1365-2141. ; 189:4, s. 689-693 Journal article (peer-reviewed)abstract In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician's choice. The five-year follow-up of this phase 3 trial showed that ofatumumab therapy resulted in a numerically but not significantly longer overall survival. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small-molecule inhibitors. Ofatumumab is a well-tolerable treatment option in multiresistant advanced CLL.

Skapa referenser, mejla, bekava och länka

Permalink

Result 1-4 of 4

Refine your search

Type of publication: conference paper (2); journal article (2)

Type of content: other academic/artistic (2); peer-reviewed (2)

Author/Editor: Kryachok, I (4); Montillo, M. (3); Grosicki, S (3); Rekhtman, G (3); Mazur, G. (3); Steurer, M. (3); show more...; Osterborg, A (2); Schuh, A (2); Andersson, PO (2); Kaplan, P (2); Daly, S. (2); Gupta, I (2); Lisby, S (2); Zaritskey, A (2); Udvardy, M (2); Chang, CN (2); Middeke, JM (2); Kulyaba, Y (2); Gorczyca, M (2); Bilous, N (1); Abramenko, I (1); Chumak, A (1); Davydova, E (1); Martina, Z (1); Bazyka, D (1); Bebeshko, V (1); Lewerin, Catharina, ... (1); Vincent, G. (1); Miklos, U. (1); Strugov, V. (1); Middeke, J. M. (1); Stefanelli, T. (1); Govindaraju, S. (1); sterborg, A. (1); show less...

University: Karolinska Institutet (4); University of Gothenburg (1)

Language: English (4)

Research subject (UKÄ/SCB): Medical and Health Sciences (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

Copyright © LIBRIS - National Library Systems
LIBRIS.kb.se

pil uppåt

Close

Copy and save the link in order to return to this view